Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

6 Feb 2018

Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease.

Metrion Biosciences has been awarded £200k funding under the Innovate UK Biomedical Catalyst Feasibility Award scheme. The funding will be used to support further development of Metrion’s in-house drug discovery pipeline.

Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

The funding will enable further preclinical development activities to be undertaken on the portfolio of small molecule potassium inhibitors acquired by Metrion from Japan Tobacco, with the aim of delivering a ‘best in class’, orally bioavailable, small molecule potassium channel inhibitor for the safe and effective treatment of a range of autoimmune diseases. This project is the first of a series of potassium channel inhibitor programmes Metrion has planned, which are designed to deliver proof of concept data on immune-sparing drug candidates, for treatment of autoimmune and neurodegenerative diseases.

Marc Rogers, Chief Scientific Officer, Metrion Biosciences, said: “We are pleased to receive this support from the Biomedical Catalyst scheme, which recognises Metrion’s contribution to R&D and drug discovery in the UK. Our team has extensive experience in the field of potassium ion channel drug discovery, having been responsible for discovery and development of three novel potassium channel therapeutics for the treatment of cardiac atrial fibrillation. We are excited to begin work on this project.”

Read More

Related news

New formulation modelling successes using ex vivo tissue

New formulation modelling successes using ex vivo tissue

9 Oct 2018

One study uses the company's proprietary TurChub model, to evaluate the diffusion and subsequent activity of drugs in human nails.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New oral treatment for metastatic melanoma receives EU authorisation

New oral treatment for metastatic melanoma receives EU authorisation

24 Sep 2018

Encorafenib in combination with binimetinib demonstrated 14.9 months median progression-free survival compared with vemurafenib monotherapy (7.3 months).

Read more 
Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
New biopharmaceutical testing laboratory to open in Geneva

New biopharmaceutical testing laboratory to open in Geneva

28 Aug 2018

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

Read more 
Exosome isolation manufacturing and characterization

Exosome isolation manufacturing and characterization

13 Aug 2018

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more